Key Developments: Glenmark Pharmaceuticals Ltd (GLEN.NS)

GLEN.NS on National Stock Exchange of India

738.15INR
22 Sep 2014
Price Change (% chg)

Rs-7.05 (-0.95%)
Prev Close
Rs745.20
Open
Rs741.70
Day's High
Rs750.00
Day's Low
Rs733.00
Volume
132,054
Avg. Vol
711,132
52-wk High
Rs790.00
52-wk Low
Rs487.60

Search Stocks

Latest Key Developments (Source: Significant Developments)

Glenmark Pharmaceuticals Ltd's TRPA1 antagonist GRC 17536 shows positive data
Wednesday, 17 Sep 2014 04:11am EDT 

Glenmark Pharmaceuticals Ltd:Says its first in class Transient Receptor Potential Ankyrin 1 (TRPA1) antagonist, GRC 17536 has shown positive data in a Phase 2a double blind, placebo controlled, multi-centre, proof of concept study conducted on 138 patients in Europe and India.A statistically significant and clinically relevant response was seen in a prospectively-identified, substantial sub-group of patients with moderate to severe pain who had relatively intact sensory responses as detected by a standardized testing methodology.GRC 17536 was well-tolerated with no evidence of CNS or other drug related side effects.  Full Article

Glenmark Pharmaceuticals enters Oncology with discovery and initation of IND enabling studies of bispecific antibody
Tuesday, 19 Aug 2014 11:18pm EDT 

Glenmark Pharmaceuticals S.A:Says discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecfic antibody.GBR 1302 is first clinical development candidate based on BEAT technology.Expects approval for initiation of clinical studies during this financial year.  Full Article

Glenmark Pharmaceuticals Ltd to set up a new manufacturing facility
Thursday, 17 Jul 2014 04:59am EDT 

Glenmark Pharmaceuticals Ltd:Plans to set up a new manufacturing facility in the US.The company plans to set up this manufacturing facility at Monroe Corporate Center, North Carolina, USA.The facility will be spread over 100,000 sq. feet (around 15 acre plot).It will first begin work on an oral solid unit and thereafter set up manufacturing units for injectables and topicals.  Full Article

Glenmark Pharmaceuticals Ltd's Glenmark Generics Inc, USA receives final ANDA approval for Fluocinonide cream
Tuesday, 15 Jul 2014 12:53am EDT 

Glenmark Pharmaceuticals Ltd:Says that Glenmark Generics Inc, USA, subsidiary of Glenmark Generics Ltd, has been granted final approval from U.S. FDA for its abbreviated new drug application (ANDA) for Fluocinonide Cream USP 0.1 pct., generic version of Vanos Cream by Medicis.  Full Article

Glenmark Pharmaceuticals's subsidiary receives final ANDA approval for Telmisartan Tablets
Tuesday, 8 Jul 2014 02:31am EDT 

Glenmark Pharmaceuticals Ltd:Glenmark Generics Inc., USA subsidiary of Glenmark Generics Limited has been granted final abbreviated new drug approval (ANDA) from the United States Food and Drug Administration (US FDA) for Telmisartan Tablets.Glenmark will commence distribution of product immediately.Telmisartan Tablets are Glenmark’s generic version of Boehringer Ingelheim’s Micardis.Telmisartan is indicated for treatment of hypertension.Approval is for 20mg, 40mg and 80mg tablets.For 12 month period ending March 2014, Telmisartan garnered annual sales of $250 mln according to IMS Health.  Full Article

Glenmark Pharmaceuticals Ltd recommends dividend
Thursday, 8 May 2014 07:27am EDT 

Glenmark Pharmaceuticals Ltd:Recommends dividend at rate of 200 pct , two Indian rupees per share (face value one Indian rupee) on Equity Share Capital for the financial year 2013-2014.  Full Article

Glenmark Pharmaceuticals Ltd monoclonal antibody GBR 900 for treatment of chronic pain entering human trials
Tuesday, 29 Apr 2014 05:43am EDT 

Glenmark Pharmaceuticals Ltd:Says that GBR 900, monoclonal antibody is entering human trials.GBR 900 targets TrkA, a receptor for nerve growth factor (NGF) involved in chronic pain signaling.In 2010, Glenmark gained an exclusive worldwide license from Lay Line Genomics S.p.A. (Italy) for anti-TrkA antibodies and their entire intellectual property portfolio in the TrkA field.GBR 900 is optimized anti-TrkA antibody emerging from this exclusive worldwide license.Glenmark completes Phase I enabling preclinical development programme for GBR 900 and has filed a Phase I clinical trial application with the MHRA, UK.  Full Article

Court of Appeals affirmed district court's decision on Glenmark Pharmaceuticals Ltd's appeal to invalidate Abbott Laboratories' TARKA
Tuesday, 22 Apr 2014 12:00am EDT 

Glenmark Pharmaceuticals Ltd:Says it loses its appeal to invalidate Abbott Laboratories' TARKA (trandolapril/verapamil hydrochloride) patent.Court of Appeals for the Federal Circuit, USA affirmed the district court's decision on April 22 regarding Glenmark's marketing of a generic equivalent of TARKA.  Full Article

Glenmark Pharmaceuticals receives final ANDA approval for Eszopiclone Tablets
Tuesday, 15 Apr 2014 11:35pm EDT 

Glenmark Pharmaceuticals Ltd:Says Glenmark Generics receives final ANDA approval for Eszopiclone Tablets.  Full Article

Glenmark Pharmaceuticals molecule GRC 27864 enters human trail
Thursday, 3 Apr 2014 05:32am EDT 

Glenmark Pharmaceuticals Ltd:Says its Chemical Entity (NCE) GRC 27864 is entering human trials.Completed preclinical studies and Phase 1 enabling GLP studies for its selected lead molecule, GRC 27864 and has filed a Phase 1 application for first-in-human trial with the MHRA, UK.Phase 1 studies are to be initiated soon and are likely to get completed by Jan. 2015.Glenmark will also be initiating a proof of concept study in patients with acute pain.  Full Article

India's Glenmark Pharma seeks foreign partners on biologic drugs

MUMBAI, July 10 - India's Glenmark Pharmaceuticals Ltd is in talks with foreign companies for a partnership on two of its biological drugs being tested for the treatment of chronic pain and autoimmune disorders, a senior executive said on Thursday.

Search Stocks